• Image courtesy of Dr Kristen Brennand & Dr Fred H. Gage/ Salk Institute for Biological Studies

    human stem cells 2
  • Image courtesy of Dr Yichen Shi and Dr Rick Livesey/ Cambridge Stem Cell Institute

    human stem cells
About EUCelLEX

The European EUCelLEX Project consists in a full examination of the application of the European rules regarding cell banks together with current practices in respect of the therapeutic use of human cells in the different countries concerned. The purpose is to submit the data obtained to the European Commission for it to draw up legislative measures in line with medical advances in this field.
The EUCelLEX project has received funding from the European Union’s FP7 and is coordinated by Emmanuelle RIAL-SEBBAG (Inserm).



REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL in accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004

COM(2014) 188 final
More information

Nature Reviews Genetics 15,220 (2014) doi:10.1038/nrg3704

AUTHORS : Timothy Caulfield, Pascal Borry & Herbert Gottweis

Increased private funding could add further to the ethical and legal complexities that are associated with biobanks.

More information

Stem Cells and Development. December 2013, 22(S1): 14-19.doi:10.1089/scd.2013.0352.

AUTHORS : Blasimme Alessandro & Rial-Sebbag Emmanuelle

Europe is ready to deploy its immense capital of knowledge into the development of effective cell-based therapies and delve into the global race for translating stem cell science into regenerative medicine. But what are the challenges and the emerging issues that lay ahead the realization of Europe’s enormous potential in this field? Both researchers and industrial stakeholders tend to impute the slow pace of translation to specific suboptimal features of the regulatory environment in Europe. At the same time, a host of new issues are emerging as testified by a recent public controversy regarding the provision of unproven cell therapy in Italy. We will review this topic and suggest some solutions to foster the responsible development of innovative cell-based therapies in Europe.

More information

Science 24 January 2014: Vol. 343 no. 6169 p. 359 DOI: 10.1126/science.343.6169.359

AUTHOR:Eliot Marchall

Opponents of the 2006 James Thomson patent say that it should be thrown out based on the same logic that led the U.S. Supreme Court to rule out patents on human genes—they are a product of nature. Even if this argument succeeds, however, many researchers say it won’t have a big impact on stem cell work because so many labs are now using a different and more artificial technology—induced pluripotent stem cells.


More information

Nature Reviews Genetics 15,82–92(2014) doi:10.1038/nrg3563

AUTHORS : Viviane Tabar and Lorenz Studer

After years of incremental progress, several recent studies have succeeded in deriving disease-relevant cell types from human pluripotent stem cell (hPSC) sources. The prospect of an unlimited cell source, combined with promising preclinical data, indicates that hPSC technology may be on the verge of clinical translation. In this Review, we discuss recent progress in directed differentiation, some of the new technologies that have facilitated the success of hPSC therapies and the remaining hurdles on the road towards developing hPSC-based cell therapies.

More information